Spots Global Cancer Trial Database for A Dose-escalation Study of LUNA18 in Patients With Locally Advanced or Metastatic Solid Tumors (With Expansion).
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Dose-escalation Study of LUNA18 in Patients With Locally Advanced or Metastatic Solid Tumors (With Expansion).
Official Title: A Phase 1 Open-label, Dose-escalation and Cohort Expansion Study of LUNA18 Monotherapy and Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors
Study ID: NCT05012618
Study Description
Brief Summary: This is a Phase 1 dose-escalation and cohort expansion study that will evaluate the safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary activity of LUNA18 when administered as a single agent or in combination with other anti-cancer drugs in patients with locally advanced or metastatic solid tumors.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
South Texas Accelerated Research Therapeutics (START) Midwest, Grand Rapids, Michigan, United States
Renown Regional Medical Center, Reno, Nevada, United States
NEXT Oncology, Austin, Texas, United States
MD Anderson Cancer Center, Houston, Texas, United States
NEXT Virginia, Fairfax, Virginia, United States
University of Wisconsin - Carbone Cancer Center, Madison, Wisconsin, United States
National Cancer Center Hospital East, Kashiwa, Chiba, Japan
National Cancer Center Hospital, Chuo-Ku, Tokyo, Japan
Contact Details
Name: Sponsor Chugai Pharmaceutical Co. Ltd
Affiliation: clinical-trials@chugai-pharm.co.jp
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
